Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients

Journal of Pharmacy and Pharmacology

Volumn 69, Issue 5, 2017, Pages 525-528

  Allegra, Sarah ^a   Cusato, Jessica ^a   De Francia, Silvia ^b   Pirro, Elisa ^b   Massano, Davide ^b   Piga, Antonio ^b   D'Avolio, Antonio ^a  

^a UNIVERSITY OF TURIN   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

AUC; iron chelator; iron overload; transfusion; thalassaemia

Indexed keywords

DEFERASIROX; BENZOIC ACID DERIVATIVE; IRON; IRON CHELATING AGENT; TRIAZOLE DERIVATIVE;

ADOLESCENT; AREA UNDER THE CURVE; ARTICLE; BETA THALASSEMIA; CHILD; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG MONITORING; FEMALE; HUMAN; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM PLASMA CONCENTRATION; TIME TO MAXIMUM PLASMA CONCENTRATION; VOLUME OF DISTRIBUTION; BETA-THALASSEMIA; COHORT ANALYSIS; IRON OVERLOAD; METABOLISM; PRESCHOOL CHILD; TREATMENT OUTCOME;

ADOLESCENT; BENZOATES; BETA-THALASSEMIA; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MALE; TREATMENT OUTCOME; TRIAZOLES;

EID: 84971323673     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/jphp.12559     Document Type: Article

References (18)

1. Cohen AR et al. Effect of transfusional iron intake on response to chelation therapy in beta-thalassemia major. Blood 2008; 111: 583–587.
2. Galanello R, Origa R. Beta-thalassemia. Orphanet J Rare Dis 2010; 5: 11.
3. Waldmeier F et al. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Drug Metab Dispos 2010; 38: 808–816.
4. Bruin GJ et al. Pharmacokinetics, distribution, metabolism, and excretion of deferasirox and its iron complex in rats. Drug Metab Dispos 2008; 36: 2523–2538.
5. Novartis, Exjade (Deferasirox) Tablets for Oral Suspension [Prescribing Information]. East Hanover, NJ: Novartis Pharmaceuticals, 2006.
6. Galanello R, Origa R. Once-daily oral deferasirox for the treatment of transfusional iron overload. Expert Rev Clin Pharmacol 2008; 1: 231–240.
7. Galanello R et al. Safety, tolerability, and pharmacokinetics of ICL670, a new orally active iron-chelating agent in patients with transfusion-dependent iron overload due to beta-thalassemia. J Clin Pharmacol 2003; 43: 565–572.
8. Chirnomas D et al. Deferasirox pharmacokinetics in patients with adequate versus inadequate response. Blood 2009; 114: 4009–4013.
9. Cappellini MD et al. Iron chelation with deferasirox in adult and pediatric patients with thalassemia major: efficacy and safety during 5 years' follow-up. Blood 2011; 118: 884–893.
10. Milat F et al. A case of hypophosphatemic osteomalacia secondary to deferasirox therapy. J Bone Miner Res 2012; 27: 219–222.
11. Cappellini MD et al. A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia. Blood 2006; 107: 3455–3462.
12. Cusato J et al. Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness. Pharmacogenomics J 2014; 15: 263–271.
13. De Francia S et al. A new HPLC UV validated method for therapeutic monitoring of deferasirox in thalassaemic patients. J Chromatogr B Analyt Technol Biomed Life Sci 2012; 893–894: 127–133.
14. Galanello R et al. Phase II clinical evaluation of deferasirox, a once-daily oral chelating agent, in pediatric patients with beta-thalassemia major. Haematologica 2006; 91: 1343–1351.
15. Piga A et al. Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. Haematologica 2006; 91: 873–880.
16. Lee JW et al. Pharmacogenetic study of deferasirox, an iron chelating agent. PLoS One 2013; 8: e64114.
17. Cusato J et al. Role of pharmacogenetics on deferasirox AUC and efficacy. Pharmacogenomics. 2016; [Epub ahead of print]
18. Cusato J et al. Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness. Pharmacogenomics J 2015; 15: 263–271.